---
title: "NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295817302.md"
description: "NeuroSense Therapeutics released a CEO shareholder letter detailing delays in the Phase 3 PARAGON study for PrimeC due to funding shortages. While FDA clearance is secured, trial initiation depends on financing. Canada's New Drug Submission is targeted for December 2026. The CEO and CFO invested $200,000 each in April. Nasdaq compliance efforts include seeking extensions and considering a reverse split ranging from 1-for-4 to 1-for-40."
datetime: "2026-08-13T14:57:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295817302.md)
  - [en](https://longbridge.com/en/news/295817302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295817302.md)
---

# NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans

-   NeuroSense published a CEO shareholder letter outlining delays in securing funding needed to start the Phase 3 PARAGON study of PrimeC in ALS. \* FDA clearance received to initiate PARAGON; trial planned to enroll about 300 participants, mainly in the US, with timing tied to financing. \* Canada regulatory push advanced; New Drug Submission for PrimeC now targeted for December 2026 following Health Canada pre-NDS discussions. \* CEO Alon Ben-Noon cited April investments of USD 200,000 each by him and CFO Or Eisenberg, alongside an existing investor. \* Nasdaq compliance efforts include seeking more time, with a proposed reverse split authorization range of 1-for-4 to 1-for-40 if needed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088851), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [NeuroSense announces shareholder letter availability](https://longbridge.com/en/news/295808294.md)
- [NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts](https://longbridge.com/en/news/295819565.md)
- [NeuroSense Issues CEO Letter to Shareholders | NRSN Stock News](https://longbridge.com/en/news/295808583.md)
- [McKesson director Bradley E. Lerman disposes of 301 common shares worth $268.789,83](https://longbridge.com/en/news/295566730.md)
- [EDM Announces DTC Eligibility for Electronic Settlement of Trades in the United States | EDMFF Stock News](https://longbridge.com/en/news/295791286.md)